Skip to main content

Table 12 Dosage of THC and CBD administered with hybrid medical cannabis to Italian fibromyalgia patients for at least 3 months

From: Medical cannabis for the treatment of fibromyalgia syndrome: a retrospective, open-label case series

Patient

Hybrid MC (Bediol and FM2), N = 18

Decoction

Oil extract

THC (mg)

CBD (mg)

THC (mg)

CBD (mg)

Patient #1

6

8

0.66

0.55

Patient #2

    

Patient #3

24

32

  

Patient #4

36

48

3.9

3.3

Patient #5

23.6

38

  

Patient #6

  

3.12

2.64

Patient #7

6

8

0.78

0.66

Patient #8

33

50

  

Patient #9

26.4

40

  

Patient #10

39.6

60

  

Patient #11

  

4.68

3.96

Patient #12

23.6

38

1.56

1.32

Patient #13

    

Patient #14

    

Patient #15

    

Patient #16

19.8

30

  

Patient #17

  

1.8

1.65

Patient #18

19.8

30

  

Median

23.6

38

1.8

2

IQR

13.2

18

3.12

2.64

Mean

23.4

34.7

2.4

2

± SD

10.7

16.1

1.6

1.3

  1. MC medical cannabis, THC Δ-9-tetrahydrocannabinol, CBD cannabidiol, N number of patients, IQR interquartile range, ± plus/minus, SD standard deviation. The table shows the quantity of THC and CBD administered with hybrid medical cannabis to 18 patients with fibromyalgia syndrome treated with medical cannabis for at least 3 months at an Italian pain clinic. Hybrid medical cannabis is the one with a similar content of Δ-9-tetrahydrocannabinol and cannabidiol